Market Overview:
The global in situ hybridization market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth of the market can be attributed to the increasing demand for in situ hybridization techniques for cancer diagnosis, immunology, neuroscience, cytology and infectious diseases applications. Additionally, the increasing use of non-radioactive labels in in situ hybridization is also contributing to the growth of this market. However, factors such as high cost and lack of skilled professionals are restraining the growth of this market. On the basis of type, radioactive isotopes held a major share of the global in situ hybridization market in 2017. This can be attributed to their ability to provide high sensitivity and specificity results compared with other types of labels used for in situ hybridization techniques.
Product Definition:
A technique used to detect the presence of a particular sequence of DNA in a tissue section or cell sample. The sequence is first identified by PCR and then labeled with a fluorescent probe. The probe is then applied to the tissue section or cell sample, where it will hybridize (bind) to any complementary sequences that are present.
Radioactive isotopes:
Isotopes are the different forms of a particular chemical element such as lead, uranium, gold, etc. The most commonly used radioactive isotopes in molecular diagnostics are radium-223 and iodine-123 which is used to diagnose thyroid cancer. Radioactive isotopes can be produced artificially by bombarding other elements with high energy particles or they can be found in nature in the form of uranium and thorium.
Non-radioactive labels:
Non-radioactive labels are used in the detection of cell types by In-Situ Hybridization (ISH). These labels are attached to the cells and then analyzed with a microscope. The most commonly used label is fluorescent dyes that can be detected with an antibody. Fluorescent dyes have been commercialized for different purposes such as biological stains, flow cytometry, and cellular imaging among others.
Application Insights:
The cancer diagnosis segment dominated the global in-situ hybridization market in 2017. This is owing to the rising prevalence of cancer and increasing demand for sensitive, specific and rapid diagnostic methods. In addition, a rise in R&D investments by various companies for developing new products related to this field is expected to boost growth over the forecast period.
For instance, last year Amgen launched AndroGel 1.5%, a testosterone gel that is designed for men who have had surgery or cannot take oral medication due to liver problems caused due to their high concentration of sex hormone binding globulin (SHBG). Similarly, CisGenomics has developed a blood test that can detect mutations associated with colorectal cancer called PanCancer Test which provides results within two weeks instead of three months as compared with other tests available in the market today. Such initiatives by key players are expected fuel growth over the forecast period (2017-2030).
Regional Analysis:
North America dominated the global in-situ hybridization market with a share of 40.0% in 2017. This is owing to the presence of well-established healthcare infrastructure, high adoption rate of advanced technologies, and increasing demand for cost-effective diagnosis methods for various diseases. Moreover, rise in R&D investment by government organizations and pharmaceutical companies is expected to drive this growth over the forecast period.
Asia Pacific region is anticipated to witness lucrative CAGR over the forecast period due to factors such as rising prevalence of cancer and infectious diseases coupled with growing medical tourism industry resulting from economic development in Asian countries such as India & China & Malaysia etc.
Growth Factors:
- Increasing demand for In-Situ Hybridization in the field of life sciences research
- Rising prevalence of cancer and other diseases
- Growing number of hybridization techniques being developed and commercialized
- Technological advancements in In-Situ Hybridization instruments and probes
- Increasing use of In-Situ Hybridization in drug discovery and development
Scope Of The Report
Report Attributes
Report Details
Report Title
In-Situ Hybridization Market Research Report
By Type
Radioactive isotopes, Non-radioactive labels
By Application
Cancer Diagnosis, Immunology, Neuroscience, Cytology, Infectious Diseases
By Companies
Abbott Laboratories, F. Hoffmann-La Roche, Leica Biosystems Nussloch, Agilent Technologies, Thermo Fisher Scientific, Merck, PerkinElmer, Exiqon A/S, BioGenex Laboratories, Advanced Cell Diagnostics, Bio SB
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global In-Situ Hybridization Market Report Segments:
The global In-Situ Hybridization market is segmented on the basis of:
Types
Radioactive isotopes, Non-radioactive labels
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer Diagnosis, Immunology, Neuroscience, Cytology, Infectious Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- F. Hoffmann-La Roche
- Leica Biosystems Nussloch
- Agilent Technologies
- Thermo Fisher Scientific
- Merck
- PerkinElmer
- Exiqon A/S
- BioGenex Laboratories
- Advanced Cell Diagnostics
- Bio SB
Highlights of The In-Situ Hybridization Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Radioactive isotopes
- Non-radioactive labels
- By Application:
- Cancer Diagnosis
- Immunology
- Neuroscience
- Cytology
- Infectious Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the In-Situ Hybridization Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
In-situ hybridization is a method of detecting and identifying nucleic acids in situ. Nucleic acids are isolated from a sample, labeled with a detectable marker, and then placed into contact with the probe molecule. The probe will hybridize to the target nucleic acid sequence and be detected by an assay system.
Some of the key players operating in the in-situ hybridization market are Abbott Laboratories, F. Hoffmann-La Roche, Leica Biosystems Nussloch, Agilent Technologies, Thermo Fisher Scientific, Merck, PerkinElmer, Exiqon A/S, BioGenex Laboratories, Advanced Cell Diagnostics, Bio SB.
The in-situ hybridization market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. In-Situ Hybridization Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. In-Situ Hybridization Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. In-Situ Hybridization Market - Supply Chain
4.5. Global In-Situ Hybridization Market Forecast
4.5.1. In-Situ Hybridization Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. In-Situ Hybridization Market Size (000 Units) and Y-o-Y Growth
4.5.3. In-Situ Hybridization Market Absolute $ Opportunity
5. Global In-Situ Hybridization Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. In-Situ Hybridization Market Size and Volume Forecast by Type
5.3.1. Radioactive isotopes
5.3.2. Non-radioactive labels
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global In-Situ Hybridization Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. In-Situ Hybridization Market Size and Volume Forecast by Application
6.3.1. Cancer Diagnosis
6.3.2. Immunology
6.3.3. Neuroscience
6.3.4. Cytology
6.3.5. Infectious Diseases
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global In-Situ Hybridization Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. In-Situ Hybridization Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global In-Situ Hybridization Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. In-Situ Hybridization Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global In-Situ Hybridization Demand Share Forecast, 2019-2029
9. North America In-Situ Hybridization Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America In-Situ Hybridization Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America In-Situ Hybridization Market Size and Volume Forecast by Application
9.4.1. Cancer Diagnosis
9.4.2. Immunology
9.4.3. Neuroscience
9.4.4. Cytology
9.4.5. Infectious Diseases
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America In-Situ Hybridization Market Size and Volume Forecast by Type
9.7.1. Radioactive isotopes
9.7.2. Non-radioactive labels
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America In-Situ Hybridization Demand Share Forecast, 2019-2029
10. Latin America In-Situ Hybridization Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America In-Situ Hybridization Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America In-Situ Hybridization Market Size and Volume Forecast by Application
10.4.1. Cancer Diagnosis
10.4.2. Immunology
10.4.3. Neuroscience
10.4.4. Cytology
10.4.5. Infectious Diseases
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America In-Situ Hybridization Market Size and Volume Forecast by Type
10.7.1. Radioactive isotopes
10.7.2. Non-radioactive labels
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America In-Situ Hybridization Demand Share Forecast, 2019-2029
11. Europe In-Situ Hybridization Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe In-Situ Hybridization Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe In-Situ Hybridization Market Size and Volume Forecast by Application
11.4.1. Cancer Diagnosis
11.4.2. Immunology
11.4.3. Neuroscience
11.4.4. Cytology
11.4.5. Infectious Diseases
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe In-Situ Hybridization Market Size and Volume Forecast by Type
11.7.1. Radioactive isotopes
11.7.2. Non-radioactive labels
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe In-Situ Hybridization Demand Share, 2019-2029
12. Asia Pacific In-Situ Hybridization Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific In-Situ Hybridization Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific In-Situ Hybridization Market Size and Volume Forecast by Application
12.4.1. Cancer Diagnosis
12.4.2. Immunology
12.4.3. Neuroscience
12.4.4. Cytology
12.4.5. Infectious Diseases
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific In-Situ Hybridization Market Size and Volume Forecast by Type
12.7.1. Radioactive isotopes
12.7.2. Non-radioactive labels
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific In-Situ Hybridization Demand Share, 2019-2029
13. Middle East & Africa In-Situ Hybridization Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa In-Situ Hybridization Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa In-Situ Hybridization Market Size and Volume Forecast by Application
13.4.1. Cancer Diagnosis
13.4.2. Immunology
13.4.3. Neuroscience
13.4.4. Cytology
13.4.5. Infectious Diseases
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa In-Situ Hybridization Market Size and Volume Forecast by Type
13.7.1. Radioactive isotopes
13.7.2. Non-radioactive labels
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa In-Situ Hybridization Demand Share, 2019-2029
14. Competition Landscape
14.1. Global In-Situ Hybridization Market: Market Share Analysis
14.2. In-Situ Hybridization Distributors and Customers
14.3. In-Situ Hybridization Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. F. Hoffmann-La Roche
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Leica Biosystems Nussloch
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Agilent Technologies
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Thermo Fisher Scientific
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. PerkinElmer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Exiqon A/S
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. BioGenex Laboratories
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Advanced Cell Diagnostics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Bio SB
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook